JDQ443 + tislelizumab

JDQ443 + tislelizumab is a combination investigational therapy comprised of JDQ443, a selective covalent inhibitor of KRAS G12C, and tislelizumab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) immune checkpoint. JDQ443 exerts antitumor activity by irreversibly binding to the mutant KRAS G12C protein in its inactive GDP-bound form, effectively blocking RAS-driven signaling pathways in cancer cells. Tislelizumab blocks PD-1, enhancing T-cell mediated immune responses against tumor cells. The combination aims to provide synergistic antitumor effects, particularly in KRAS G12C-mutated advanced solid tumors, such as non-small cell lung cancer (NSCLC), by both directly inhibiting cancer cell proliferation (JDQ443) and enabling immune-mediated tumor eradication (tislelizumab). The combination is being investigated in ongoing clinical trials for safety and efficacy[1][3][5].

Other names

JDQ443 plus tislelizumabJDQ-443 plus tislelizumabJDQ 443 plus tislelizumab